In this paper, we present evidence that the Korean red ginseng extract shows the immunomodulatory activities during postoperative chemotherapy after curative surgery in patients with advanced colon cancer. We measured the circulating interleukin-2 (IL-2), interleukin-8 (IL-8)and interleukin-10 (IL-1...
In this paper, we present evidence that the Korean red ginseng extract shows the immunomodulatory activities during postoperative chemotherapy after curative surgery in patients with advanced colon cancer. We measured the circulating interleukin-2 (IL-2), interleukin-8 (IL-8)and interleukin-10 (IL-10) as a immune modulator to evaluate the effect of Korean red ginseng. The mean preoperative value of IL-2 was similar in the non-RG group and the RG group (5.72 pg/ml versus 6.87 pg/ml, p>0.05). The mean value of IL-2 was compared with IL-2 from healthy control group, there was no significant difference (14.89 pg/ml versus 14.22 pg/ml, p>0.05). The mean preoperative value of IL-8 was higher in the non-RG group comparing with the RG group (30.92 pg/ml versus 36.25 pg/ml, p 0.05). The preoperative mean value of IL-10 of non-RG, RG and HC group was 11.56 pg/ml, 10.8 pg/ml, and 3.68 pg/ml respectively. At postoperative 3 month, the mean values of IL-10 from non-RG and RG group down to 8.45 pg/ml and 5.04 pg/ml respectively. In spite of decreasing IL-10 levels of both cancer Patients group with time, there was still significant difference with that of HC group (non-RG versus HC group, p=0.00, RC versus HC group, p=0.04). The results of this study suggest that the red ginseng extract may have some immunomodulatory properties associated with IL-2, IL-8 and IL-10 activity in patients with advanced colorectal cancer during postoperative chemotherapy. We think to need the further studies and a larger sample size to fully evaluate the antitumor effect of ginseng and need to establish this mechanism of action as well as identify the active components associated with antitumor activity and immunomodulation in patients with advanced colorectal cancer.
In this paper, we present evidence that the Korean red ginseng extract shows the immunomodulatory activities during postoperative chemotherapy after curative surgery in patients with advanced colon cancer. We measured the circulating interleukin-2 (IL-2), interleukin-8 (IL-8)and interleukin-10 (IL-10) as a immune modulator to evaluate the effect of Korean red ginseng. The mean preoperative value of IL-2 was similar in the non-RG group and the RG group (5.72 pg/ml versus 6.87 pg/ml, p>0.05). The mean value of IL-2 was compared with IL-2 from healthy control group, there was no significant difference (14.89 pg/ml versus 14.22 pg/ml, p>0.05). The mean preoperative value of IL-8 was higher in the non-RG group comparing with the RG group (30.92 pg/ml versus 36.25 pg/ml, p 0.05). The preoperative mean value of IL-10 of non-RG, RG and HC group was 11.56 pg/ml, 10.8 pg/ml, and 3.68 pg/ml respectively. At postoperative 3 month, the mean values of IL-10 from non-RG and RG group down to 8.45 pg/ml and 5.04 pg/ml respectively. In spite of decreasing IL-10 levels of both cancer Patients group with time, there was still significant difference with that of HC group (non-RG versus HC group, p=0.00, RC versus HC group, p=0.04). The results of this study suggest that the red ginseng extract may have some immunomodulatory properties associated with IL-2, IL-8 and IL-10 activity in patients with advanced colorectal cancer during postoperative chemotherapy. We think to need the further studies and a larger sample size to fully evaluate the antitumor effect of ginseng and need to establish this mechanism of action as well as identify the active components associated with antitumor activity and immunomodulation in patients with advanced colorectal cancer.
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
문제 정의
Despite varied treatment strategies, the control of the colon cancer with an advanced stage remains yet problematic. The aim of this study was to prospectively evaluate the effect of the red ginseng on postoperative host immunity 1 in patients of advanced colon cancer. The authors prospectively investigated the circulating interleukin-2 (IL-2), Interleukin-8 (IL-8), Interleukin-10 (IL-10) according to ingestion of the red ginseng in patients with advanced colon cancer who had underwent the curative resection with postoperative chemotherapy.
제안 방법
5-FU and leuko- vorin (375 mg/m2/day and 30 mg IV/bolus/day) regimen was administered by continuous infusion. All patients were randomly allocated into two groups before operation: patients designated to receive the red ginseng (RG group, n = 24) and control group (non-RG group, n = 23). The RG group took the red ginseng extract (Korea Ginseng Corporation, Seoul, Korea) orally at a dosage of 3 g/ day during the first three months after operation.
After exclusion criteria, 47 patients were eligible and enrolled in this study. All patients were treated with 5-Fu +leukovoTin chemotherapy every month during the first six months after the curative operation. 5-FU and leuko- vorin (375 mg/m2/day and 30 mg IV/bolus/day) regimen was administered by continuous infusion.
The patients were identified preoperatively between July 1, 2005 and February 30, 2006. Datas regarding clinical characteristics were collected and evaluated by a blinded, independent surgeon. Patients were excluded from this study if they had: (1) perioperative or postoperative transfusion required during follow-up, (2) postoperative major complications such as single or multiple organ failure, sepsis, pneumonia, anastomosis leakage, intrabdominal infection or abscess, (3) reoperation, (4) failure to maintain the ingestion of the red ginseng extract, (5) failure in regular follow-up, or (6) death unrelated to primary cancer, or (7) chronic medical illness such as hypertension, diabetes mellitus, and chronic obstructive pulmonary diseases, etc.
The aim of this study was to prospectively evaluate the effect of the red ginseng on postoperative host immunity 1 in patients of advanced colon cancer. The authors prospectively investigated the circulating interleukin-2 (IL-2), Interleukin-8 (IL-8), Interleukin-10 (IL-10) according to ingestion of the red ginseng in patients with advanced colon cancer who had underwent the curative resection with postoperative chemotherapy.
대상 데이터
Patients were excluded from this study if they had: (1) perioperative or postoperative transfusion required during follow-up, (2) postoperative major complications such as single or multiple organ failure, sepsis, pneumonia, anastomosis leakage, intrabdominal infection or abscess, (3) reoperation, (4) failure to maintain the ingestion of the red ginseng extract, (5) failure in regular follow-up, or (6) death unrelated to primary cancer, or (7) chronic medical illness such as hypertension, diabetes mellitus, and chronic obstructive pulmonary diseases, etc. After exclusion criteria, 47 patients were eligible and enrolled in this study. All patients were treated with 5-Fu +leukovoTin chemotherapy every month during the first six months after the curative operation.
Forty-seven patients who had undergone the curative colon resection by the same surgeon for histolopathologi- cally proven AJCC stage Ⅲ colon adenocarcinoma were considered eligible for this study. The patients were identified preoperatively between July 1, 2005 and February 30, 2006.
eligible for this study. The patients were identified preoperatively between July 1, 2005 and February 30, 2006. Datas regarding clinical characteristics were collected and evaluated by a blinded, independent surgeon.
성능/효과
The clinical and histopathological details of all patients with AJCC stage Ⅲ colon cancer studied are shown in Table 1. There were no significant statistical differences between the RG and non-RG groups based on age, sex ratio, AJCC stage, depth of tumor invasion, regional lymph node metastasis, tumor size, proximal resection margin and distal resection margin.
후속연구
during postoperative chemotherapy. But further studies need a larger sample size to fully evaluate the antitumor effect of ginseng and need to establish this mechanism of action as well as identify the active components associated with antitumor activity and immunomodulation in patients with advanced colon cancer.
참고문헌 (22)
Chong, S.K. and Oberholzer, V.G.: Ginseng-Is there a use in clinical medicine? Postgrad. Med. J. 64, 841-846 (1988)
Mochizuki, M., Yoo, Y.C., Matsuzawa, K., Sato, K., Saiki, I., Tono-oka, S., Samukawa, K. and Azuma, I.: Inhibitory effect of tumor metastasis in mice by saponins, ginsenoside-Rb2, 20(R)- and 20(S)-ginsenoside-Rg3, of red ginseng. Biol. Pharm. Bull. 18, 1197-1202 (1995)
Sato, K., Mochizuki, M., Saiki, I., Yoo, Y.C., Samukawa, K. and Azuma, I.: Inhibition of tumor angiogenesis and metastasis by a saponin of Panax ginseng, ginsenoside-Rb2. Biol. Pharm. Bull. 17, 635-639 (1995)
Xiaoguang, C., Hongyan, L., Xiaohong, L., Zhaodi, F., Yan, L., Lihua, T., Rui, H.: Cancer chemopreventive and therapeutic activities of red ginseng. J. Ethnopharmacol. 60, 71-78 (1998)
Wakabayashi, C., Murakami, K., Hasegawa, H., Murata, J. and Saiki, I.: An intestinal bacterial metabolite of ginseng protopannaxadiol saponins has the ability to induce apoptosis in tumor cells. Biol. Pharm. Bull. 246, 725-730 (1998)
Lee, Y.S., Chung, I.S., Lee, I.R., Kim, K.H., Hong, W.S. and Yun, Y.S.: Activation of multiple effector pathways of immune system by the antineoplastic immunostimulator acidic polysaccharide ginsan isolated from Panax ginseng. Anticancer Res. 17, 323-331 (1997)
Kaszubowski, P.A., Husby, G., Tung, K.S.K. and Williams, R.C. Jr.: T-lymphocyte subpopulations in peripheral blood and tissues of cancer patients. Cancer Res. 40, 4648-4657 (1980)
Yun, T.K. and Choi, S.Y.: Preventive effect of ginseng intake against various human cancers: a casecontrol study on 1987 pairs. Cancer Epidemiol. Biomarkers Prev. 4, 401-408 (1995)
Iishi, H., Tatsuta, M., Baba, M., Uehara, H., Nakaizumi, A., Shinkai, K., Akedo, H., Funai, H., Ishiguro, S. and Kitagawa, I.: Inhibition by ginsenoside Rg3 of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in Wistar rats. Clin. Exp. Metastasis 15, 603-611 (1997)
Lee, Y.J., Chung, E., Lee, K.Y., Lee, Y.H., Huh, B. and Lee, S.K.: Ginsenoside-Rg1, one of the major active molecules from Panax ginseng, is a functional ligand of glucocorticoid receptor. Mol. Cell. Endocrinol. 20, 135-140 (1997)
Matsunaga, H., Katano, M., Yamamoto, H., Mori, M. and Takata, K.: Studies on the panaxytriol of Panax ginseng C. A. Meyer. Isolation, determination and antitumor activity. Chem. Pharm. Bull. 37, 1279-1281 (1989)
Odashima, S., Nakayabu, Y., Honjo, N., Abe, H. and Arichi, S.: Induction of phenotypic reverse transformation by ginsenosides in cultured Morris hepatoma cells. Eur. J. Cancer 15, 885-892 (1979)
Akiyoshi, T., Koba, F., Arinaga, S. and Ueo, H.: Preoperative cell-mediated immune function and the prognosis of patients with gastric carcinoma. J. Surg. Oncol. 45, 137-142 (1990)
Sugiyama, Y., Sakata, K., Saji, S., Takao, H. and Hamuro, J.: Effects of serum immunosuppressive factors on antitumor cytotoxicity of interleukin 2-induced lymphocytes. J. Surg. Oncol. 35, 223-229 (1987)
Tsubono, M., Nio, Y., Shiraishi, T., Morimoto, H., Tseng, C.C., Kawabata, K., Masai, Y., Fukumoto, M. and Tobe, T.: Increased number of suppressor T-cells and impaired IL-2 mediated T-cell function in peripheral blood of gastric cancer patients. J. Clin. Lab. Immunol. 33, 107-115 (1990)
Kim, K.H., Lee, Y.S., Jung, I.S., Park, S.Y., Chung, H.Y., Lee, I.R. and Yun, Y.S.: Acidic polysaccahride from Panax ginseng, ginsan, induces Th1 cell and macrophage cytokines and generates LAK cells in synergy with rIL-2. Planta Med 64, 110-115 (1998)
Brew, R., Southern, S.A., Flanagan, B.F., McDicken, I.W. and Christmas, S.E.: Detection of interleukin-8 mRNA and protein in human colorectal carcinoma cells. Eur J Cancer 32A(12), 2142-2147 (1996)
Evans, C., Morrison, I., Heriot, A.G., Bartlett, J.B., Finlayson, C., Dalgleish, A.G？？. and Kumar, D.: The correlation between colorectal cancer rates of proliferation and apoptosis and systemic cytokine levels; plus their influence upon survival. Br J Cancer 94(10), 1412-1419 (2006)
Sung Ock Suh, Jin Kim and Ming Young Cho.: The prospective Study for Korean Red Ginseng Extract as an Immune Modulator following a Curative Gastric Resection with Advanced Gastric Cancer. J. Ginseng Res. 28 (2004)
Sung Ock Suh, Matthew Koh, Nam Ryeol Kim and Ming Young Cho Effect of Red Ginseng uopn Postoperative Immunity and Survival in Patients with Stage III gastric Cancer. The Amercan J. of Chinese Med. 30, 483-494 (2002)
※ AI-Helper는 부적절한 답변을 할 수 있습니다.